Glucagon-like receptor 1 agonists and DPP-4 inhibitors: potential therapies for the treatment of stroke (Q26861493)

title

Glucagon-like receptor 1 agonists and DPP-4 inhibitors: potential therapies for the treatment of stroke (English)

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25669907%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Martin Larsson

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25669907%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Cesare Patrone

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25669907%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

author name string

David Nathanson

3

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25669907%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Thomas Klein

4

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25669907%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Thomas Nyström

5

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25669907%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

language of work or name

1 reference

May 2015

1 reference

Journal of Cerebral Blood Flow & Metabolism

published in

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25669907%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

volume

35

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25669907%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

page(s)

718-723

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25669907%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

issue

5

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25669907%20AND%20SRC:MED&resulttype=core&format=json

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

2 June 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4420864

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4420864

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4420864

Dipeptidyl peptidase-4 inhibitors do not increase the risk of cardiovascular events in type 2 diabetes: a cohort study

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4420864

Exendin-4 reduces ischemic brain injury in normal and aged type 2 diabetic mice and promotes microglial M2 polarization

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4420864

Antidiabetic treatment, stroke severity and outcome

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4420864

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4420864

Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4420864

Alogliptin, a dipeptidylpeptidase-4 inhibitor, for patients with diabetes mellitus type 2, induces tolerance to focal cerebral ischemia in non-diabetic, normal mice.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4420864

The DPP-4 inhibitor linagliptin counteracts stroke in the normal and diabetic mouse brain: a comparison with glimepiride

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4420864

Glucagon-like peptide-1 decreases intracerebral glucose content by activating hexokinase and changing glucose clearance during hyperglycemia

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4420864

Glucagon-like peptide-1 receptor activation reduces ischaemic brain damage following stroke in Type 2 diabetic rats

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4420864

Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4420864

Exendin-4, a glucagon-like peptide-1 receptor agonist, provides neuroprotection in mice transient focal cerebral ischemia

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4420864

Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4420864

Reducing the risk of stroke in type 2 diabetes: pathophysiological and therapeutic perspectives

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4420864

GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4420864

Neuroprotection for ischemic stroke: two decades of success and failure

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4420864

Neuroprotective effects of liraglutide for stroke model of rats

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4420864

Dipeptidyl peptidase IV, aminopeptidase N and DPIV/APN-like proteases in cerebral ischemia

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4420864

Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease.

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4420864

Ischemia-induced changes in glucagon-like peptide-1 receptor and neuroprotective effect of its agonist, exendin-4, in experimental transient cerebral ischemia.

19 June 2018

1 reference

https://api.crossref.org/works/10.1038%2FJCBFM.2015.17

Neuroprotective and anti-apoptotic effects of liraglutide in the rat brain following focal cerebral ischemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJCBFM.2015.17

Exenatide in acute ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJCBFM.2015.17

Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJCBFM.2015.17

Pleiotropic mechanisms for the glucose-lowering action of DPP-4 inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJCBFM.2015.17

Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJCBFM.2015.17

2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial

21 January 2018

1 reference

https://pubmed.ncbi.nlm.nih.gov/25669907

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Activation of spinal glucagon-like peptide-1 receptors specifically suppresses pain hypersensitivity

1 reference

https://pubmed.ncbi.nlm.nih.gov/25669907

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Repeated administration of exendin-4 reduces focal cerebral ischemia-induced infarction in rats

1 reference

https://pubmed.ncbi.nlm.nih.gov/25669907

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/JCBFM.2015.17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25669907%20AND%20SRC:MED&resulttype=core&format=json

release_7bozwv6fzbazpmybj5vgpobf7e

2 June 2020

Fatcat ID

0 references

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25669907%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

2 references